Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/27844
Title: Clinical and EEG factors associated with antiseizure medication resistance in idiopathic generalized epilepsy.
Austin Authors: Kamitaki, Brad K;Janmohamed, Mubeen;Kandula, Padmaja;Elder, Christopher;Mani, Ram;Wong, Stephen;Perucca, Piero ;O'Brien, Terence J;Lin, Haiqun;Heiman, Gary A;Choi, Hyunmi
Affiliation: Comprehensive Epilepsy Program
Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia
Neurology Department, Alfred Hospital, Melbourne, Victoria, Australia
Departments of Medicine and Neurology, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia
Department of Neurology, Cornell University, New York, NY, USA
Department of Neurology, Columbia University, New York, New York, USA
Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
School of Nursing, Rutgers, the State University of New Jersey, Newark, New Jersey, USA
Department of Genetics, Human Genetics Institute of New Jersey, Rutgers, the State University of New Jersey, Piscataway, New Jersey, USA
Department of Neurology, Columbia University, New York, New York, USA
Medicine (University of Melbourne)
Issue Date: 27-Oct-2021
Date: 2021-10-27
Publication information: Epilepsia 2022; 63(1): 150-161
Abstract: We sought to determine which combination of clinical and electroencephalography (EEG) characteristics differentiate between an antiseizure medication (ASM)-resistant vs ASM-responsive outcome for patients with idiopathic generalized epilepsy (IGE). This was a case-control study of ASM-resistant cases and ASM-responsive controls with IGE treated at five epilepsy centers in the United States and Australia between 2002 and 2018. We recorded clinical characteristics and findings from the first available EEG study for each patient. We then compared characteristics of cases vs controls using multivariable logistic regression to develop a predictive model of ASM-resistant IGE. We identified 118 ASM-resistant cases and 114 ASM-responsive controls with IGE. First, we confirmed our recent finding that catamenial epilepsy is associated with ASM-resistant IGE (odds ratio [OR] 3.53, 95% confidence interval [CI] 1.32-10.41, for all study subjects) after covariate adjustment. Other independent factors seen with ASM resistance include certain seizure-type combinations (absence, myoclonic, and generalized tonic-clonic seizures [OR 7.06, 95% CI 2.55-20.96]; absence and generalized tonic-clonic seizures [OR 4.45, 95% CI 1.84-11.34]), as well as EEG markers of increased generalized spike-wave discharges (GSWs) in sleep (OR 3.43, 95% CI 1.12-11.36 for frequent and OR 7.21, 95% CI 1.50-54.07 for abundant discharges in sleep) and the presence of generalized polyspike trains (GPTs; OR 5.49, 95% CI 1.27-38.69). The discriminative ability of our final multivariable model, as measured by area under the receiver-operating characteristic curve, was 0.80. Multiple clinical and EEG characteristics independently predict ASM resistance in IGE. To improve understanding of a patient's prognosis, clinicians could consider asking about specific seizure-type combinations and track whether they experience catamenial epilepsy. Obtaining prolonged EEG studies to record the burden of GSWs in sleep and assessing for the presence of GPTs may provide additional predictive value.
URI: https://ahro.austin.org.au/austinjspui/handle/1/27844
DOI: 10.1111/epi.17104
ORCID: 0000-0001-7600-7805
0000-0001-8601-3686
0000-0002-7855-7066
0000-0001-5859-0259
0000-0002-0826-2350
Journal: Epilepsia
PubMed URL: 34705264
Type: Journal Article
Subjects: case-control study
catamenial
epidemiology
outcome
prognosis
Appears in Collections:Journal articles

Show full item record

Page view(s)

38
checked on Nov 8, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.